We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Woodcock, AAM Testify on REMS Programs Delaying Generic Competition
Woodcock, AAM Testify on REMS Programs Delaying Generic Competition
The FDA has received 150 inquiries from generic companies that have had trouble accessing samples, CDER Director Janet Woodcock told lawmakers at a House oversight subcommittee hearing.